SCHEMBL424221

SCHEMBL424221

CN(C(=O)n1cnc(-c2cccnc2)c1)C1CCNCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.54
CES2 O00748 1/20 0.54
CYP2A6 P11509 4/20 0.45
CYP2E1 P05181 3/20 0.45
CYP2C9 P11712 3/20 0.45
CYP2B6 P20813 3/20 0.45
CYP2C19 P33261 3/20 0.45
DYRK1A Q13627 2/20 0.43
CYP3A4 P08684 3/20 0.43
PLAT P00750 1/20 0.41
PIM1 P11309 5/20 0.41
MKNK1 Q9BUB5 2/20 0.41
MKNK2 Q9HBH9 2/20 0.41
CYP1A2 P05177 2/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
ALOX15 P16050 1/20 0.39
HIF1A Q16665 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CDK1 P06493 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL446840 0.93 FAAH (0.48) FAAHCES2CYP2A6CYP2E1CYP2C9
SCHEMBL426094 0.90 FAAH (0.66) FAAHCES2CYP2A6CYP2E1CYP2C9
SCHEMBL427429 0.90 FAAH (0.59) FAAHCES2CYP2D6
SCHEMBL424140 0.89 FAAH (0.67) FAAHCES2CYP2A6CYP2E1CYP2C9
SCHEMBL427890 0.88 FAAH (0.55) FAAHCES2CYP2A6CYP2E1CYP2C9
SCHEMBL427343 0.87 FAAH (0.54) FAAHCES2CYP2A6CYP2E1CYP2C9
SCHEMBL427505 0.85 FAAH (0.52) FAAHCES2CYP2A6CYP2E1CYP2C9
SCHEMBL16433307 0.85 FAAH (0.54) FAAHCES2MKNK1MKNK2
SCHEMBL424938 0.84 FAAH (0.52) FAAHCES2CYP2A6CYP2E1CYP2C9
SCHEMBL428013 0.84 FAAH (0.53) FAAHCES2CYP1A2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
CN-102333568-A Pharmaceutical compounds BIAL PORTELA & CA SA 2012-01-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885CES2 62/4885CYP2A6 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.